Orasis Pharmaceuticals: Valuation, Funding & Investors
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to advancing vision care through innovative solutions. The company is focused on the development and commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel eye drop designed to treat presbyopia in adults.
Leadership & Board
- Current Number of Employees
- 66
- Current LinkedIn Followers
- 8,326
Latest Estimated Valuation
- Total Amount Raised
- $78M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $78M
- Latest Funding Round
- Series D
Employee Trend
Orasis Pharmaceuticals had 66 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
66Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Orasis Pharmaceuticals had 8,326 followers as of November 16, 2026. The number of followers increased by 16 (0.19%) week-over-week.
8,326Latest Followers Count
16(0.19%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series D | $78.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Sequoia Capital | Series D |
| Arboretum Ventures | Series D |
| Johnson & Johnson Innovation – JJDC Inc. | Series D |
| Catalio Capital Management | Series D |
| Freepoint Capital Group | Series D |
| Visionary Ventures | Series D |
| Bluestem Capital | Series D |
| SBI | Series D |
Similar Companies
A snapshot of private companies similar to Orasis Pharmaceuticals, helping you discover and navigate related company profiles.
Related News and Analysis









